21-8月-2018 – CRI Report

Global In-vitro Fertilization Market Research Report – Forecast to 2023

admin — Mon, 15 Oct 2018 03:21:23 +0000

In-vitro fertilization (IVF) has become an established treatment option for different forms of infertility. IVF procedures help infertile people to conceive. IVF provides women the opportunity to become pregnant using her own eggs or donor’s eggs and sperm from her partner or from a sperm donor. As the IVF procedure is quite expensive, people generally try out other options. In case of failure in other treatments, IVF remains as the only option for the people longing to experience parenthood. Additionally, in certain cases, IVF is chosen if the parents are fearful of passing certain genetic disorders to the child. The embryos can be tested for genetic abnormalities in medical labs prior to implantation.
The factors such as the rise in the rate of infertility and surrogacy in developing countries, increasing occurrence of reproductive tourism, and high success rate of IVF are anticipated to be the drivers for the growth of the market. Additionally, the changing lifestyle in urban areas and increased age of parenthood are expected to boost the growth of the market. Despite the drivers, the high cost related to assisted reproductive techniques (ART) may hamper the growth of the global in-vitro fertilization market.
The global in-vitro fertilization market has been segmented based on product, type, end-user, and region.
Based on product, the market is segmented into devices and reagents. The devices segment is further segmented into imaging systems, sperm separation system, ovum aspiration pump, cerosystem, and micromanipulator. The reagent segment is segmented into embryo culture media, cryopreservation media, sperm processing media, and ovum processing media.
Based on type, the market is segmented into intrauterine insemination (IUI), in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and IVF using donor eggs.
Based on end-user, the market is segmented into fertility clinics, hospitals, clinical research centers, and others.
The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023.
Key Players
Cook Medical, Cooper Surgical Fertility, Merck KGaA, Thermo Fisher Scientific, INVO Bioscience, Irvine Scientific, GENEA BIOMEDX, Vitrolife, Oxford Gene Technology, Genea Limited, and others.
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the in-vitro fertilization market
• To provide insights into factors affecting the market growth
• To analyze the global in-vitro fertilization market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by product, type, end-user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the in-vitro fertilization market

Target Audience
• IVF device manufacturers & suppliers
• Biotechnology companies
• Fertility clinics
• Hospitals & clinics
• Academic research institutes
• Government institutes
Key Findings
• The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023
• Based on product, the devices segment accounted for the largest market share of 53.5% in 2017, with a market value of USD 3,739.7 million in 2017
• Based on type, the intrauterine insemination (IUI) segment accounted for the largest market share of 35.4% in 2017, with a market value of USD 2,470.3 million
• Europe holds the largest share of the global in-vitro fertilization market which is expected to reach USD 5,074.1 million by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 11.05 % from 2018 to 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global In-vitro Fertilization Market Research Report – Forecast to 2023 first appeared on CRI Report.

Global Circulating Tumor Cell Market Research Report – Forecast to 2023

admin — Mon, 08 Oct 2018 03:08:16 +0000

Circulating tumor cells (CTCs) are cancer cells that are separated from the solid tumor and enter the bloodstream. Circulating tumor cells can be used as a blood biomarker for the early diagnosis of carcinogenesis and cancer and help to monitor metastatic breast, colorectal, and prostate cancers.
The growth of the circulating tumor cells market can be driven by the growing prevalence of cancer, rising research and development in the biotechnology and pharmaceutical industry, and rising geriatric population. The growing prevalence of cancer is driving the growth of the market, as circulating tumor cells find their applications in the diagnosis of cancer and precision management. For instance, the National Center for Biotechnology Information (NCBI) stated that the projected cases of prostate cancer all over India for the year 2015 were 28,079. Furthermore, the Leukemia & Lymphoma Society estimated that around, 60,300 people are expected to be diagnosed with leukemia in 2018. The significant growth in the population of cancer patients is paving a way for the growth of the circulating tumor cells market.
Similarly, according to the National Health and Medical Research Council, the Australian government spent over USD 174.6 million on cancer research and development. This growing research and development in the field of healthcare are leading to the growth of the circulating tumor cells market.
The global circulating tumor cells market is segmented based on application, technology, and end-user.
Based on application, the market is further segmented into clinical, research, and drug development.
Based on technology, the market is segmented into CTC enrichment, CTC detection, and combined enrichment and separation of CTC (CTC analysis).
Based on end-user, the market is segmented into hospitals and clinics, research and academic institutes, and diagnostic centers.
The global circulating tumor cells market was valued USD 9393.1 million in 2017 and is expected to register a CAGR of 20.32% % over the forecast period.
Key Players
Greiner Bio-One International GmbH, Ikonisys Inc., Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc., Fluxion Biosciences, Inc., and GE Healthcare, among others.
Study objectives
To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global circulating tumor cells market.
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global circulating tumor cells market
• To provide a detailed analysis of the value chain and supply chain of the global circulating tumor cells market
Target Audience
• Pharmaceutical and Biotechnology Companies
• Medical Devices Companies
• Research and Development (R&D) Institutes
• Market Research and Consulting Service Providers
• Potential Investors
Key Findings
• The global circulating tumor cells market is expected to reach USD 28,399.2million by 2023 at a CAGR of 20.32% from 2018 to 2023
• On the basis of application, the clinical segment accounted for the major market share of 63% and was valued at USD 5,920.9 million in 2017
• On the basis of technology, the CTC enrichment accounted for a major market share of 58.5% in 2017
• The Americas holds the largest share of the global circulating tumor cells market which is expected to reach USD 13,011.5 million by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 20.84% from 2018 to 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Western Europe
 Germany
 UK
 France
 Italy
 Spain
 Rest of Western Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Circulating Tumor Cell Market Research Report – Forecast to 2023 first appeared on CRI Report.

Global Immortalized Cell Line Market Research Report – Forecast to 2023

admin — Mon, 08 Oct 2018 03:08:03 +0000

Immortalized Cell Line Market

Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. HepaRG and Hep G2 cell lines are most frequently used for toxicity studies among the currently available human hepatic cell lines.

The immortalized cell line plays a vital role in cell biology while studying multicellular organisms and their biochemistry. The demand for immortalized cell lines is increasing and so as the applications. The increasing adoption of immortalized cell lines in stem cell therapy drives the growth of the market.

Besides, the increasing awareness regarding the use of cell lines in healthcare, rising vaccines production, increasing application of cell lines in cancer therapy, and use of innovative technology for cell lines have fueled the growth of the market. On the other hand, the high cost of equipment and difficulties in developing a stable and authentic strain have restrained the growth of the immortalized cell line market.

Moreover, continuous cell lines are widely used by numerous pharmaceutical and biotech-based companies as a specimen for testing the drug efficacy. Due to this, there is a reduction in the use of gnotobiotic animals such as mice, rabbits, and monkeys, among others. Moreover, as these cell lines have a long shelf life and can be easily preserved via cryopreservation and lyophilization techniques, several biotech and pharmaceutical companies are preferring them over other media cultures for performing their R&D activities.

For instance, as per a report published by the Department of Pharmaceutical Sciences and Bio Manufacturing Research Institute and Technology Enterprises (BRITE), in 2014, around 1.3 USD billion capital was invested in new pharmaceuticals for drug discovery through cell line culture.

The global immortalized cell line market is segmented based on method, application, and end-user.

Based on method, the market is further segmented into virus induction, HTERT expression, inactivation of tumor, suppression genes, and others.

Based on application, the market is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.

Based on end-user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, and research laboratories.

The global immortalized cell line market was valued at USD 2,421.34 million in 2017 and is expected to register a CAGR of 9.30% during the forecast period from 2018 to 2023.

Key Players
Lonza Group AG, Corning Incorporated, Thermo Fisher Scientific, Selexis SA, Valneva, European Collection of Authenticated Cell Cultures (ECACC), Sartorius AG, ATCC (American Type Culture Collection Inc.), Merck KGaA, and Wuxi App Tec, and others

Study objectives
To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immortalized cell line market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a

competitive landscape for the market
• To provide economic factors that influence the global immortalized cell line market
• To provide a detailed analysis of the value chain and supply chain of the global immortalized cell line market

Target Audience
• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Key Findings
• The global immortalized cell line market is expected to reach USD 4,105.62 million by 2023 at a CAGR of 9.30% from 2018 to 2023
• On the basis of method, virus induction accounted for the largest market share of 39.9% in the year 2017 and was valued at USD 965.97 million in the same year
• On the basis of application, diagnostic accounted for the largest market share of 32.1% in 2017
• The Americas holds the largest share of the global immortalized cell line market which is expected to reach USD 1,505.38 million by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 10.04 % from 2018 to 2023

Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Immortalized Cell Line Market Research Report – Forecast to 2023 first appeared on CRI Report.